연구성과로 돌아가기
2023 연구성과별 연구자 정보 (293 / 2675)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | Heo, Jeong | Heo, J | 11 | Pusan Natl Univ, Coll Med, Busan, Peoples R China | MHQ-1390-2025 | Heo, Jeong | 0000-0003-0961-7851 | Heo, Jeong | pierce.chow@duke-nus.edu.sg; | |
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | Heo, Jeong | Heo, J | 11 | Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea | MHQ-1390-2025 | Heo, Jeong | 0000-0003-0961-7851 | Heo, Jeong | pierce.chow@duke-nus.edu.sg; | |
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | Tak, Won Young | Tak, WY | 12 | Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Immunol, Daegu, South Korea | 0000-0001-8145-1900 | Yu, Ming-Lung | pierce.chow@duke-nus.edu.sg; | |||
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | Nakamura, Shinichiro | Nakamura, S | 13 | Himeji Red Cross Hosp, Himeji, Hyogo, Japan | pierce.chow@duke-nus.edu.sg; | |||||
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | Numata, Kazushi | Numata, K | 14 | Yokohama City Univ, Med Ctr, Yokohama, Japan | pierce.chow@duke-nus.edu.sg; | |||||
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | Uguen, Thomas | Uguen, T | 15 | Hop Pontchaillou, Rennes, France | pierce.chow@duke-nus.edu.sg; | |||||
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | Hsiehchen, David | Hsiehchen, D | 16 | Univ Texas Southwestern Med Ctr, Dept Internal Med, Div Hematol & Oncol, Dallas, TX USA | pierce.chow@duke-nus.edu.sg; | |||||
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | Cha, Edward | Cha, E | 17 | Genentech South San Francisco, San Francisco, CA USA | pierce.chow@duke-nus.edu.sg; | |||||
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | Hack, Stephen P. | Hack, SP | 18 | Genentech South San Francisco, San Francisco, CA USA | pierce.chow@duke-nus.edu.sg; | |||||
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | Lian, Qinshu | Lian, QS | 19 | Genentech South San Francisco, San Francisco, CA USA | pierce.chow@duke-nus.edu.sg; | |||||
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | Ma, Ning | Ma, N | 20 | Genentech South San Francisco, San Francisco, CA USA | pierce.chow@duke-nus.edu.sg; | |||||
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | Spahn, Jessica H. | Spahn, JH | 21 | Genentech South San Francisco, San Francisco, CA USA | pierce.chow@duke-nus.edu.sg; | |||||
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | Wang, Yulei | Wang, YL | 22 | Genentech South San Francisco, San Francisco, CA USA | AAG-2845-2020 | Wang, Yulei | 0009-0002-9642-9460 | Fanello, Silvia | pierce.chow@duke-nus.edu.sg; | |
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | Wu, Chun | Wu, C | 23 | Roche China Holding, Shanghai, Peoples R China | pierce.chow@duke-nus.edu.sg; | |||||
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | Chow, Pierce K. H. | Chow, PKH | 24 | 교신저자 | Natl Canc Ctr Singapore, Singapore, Singapore | pierce.chow@duke-nus.edu.sg; |
페이지 이동: